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Abstract
Background: The epidermal growth factor receptor (EGFR) signaling pathway is important in regulating biological
behaviors in many malignancies. We explored whether expression and activation of EGFR and several components
on its downstream pathways have prognostic significance in patients with esophageal squamous cell carcinoma
(ESCC).
Methods: Expression of EGFR, phosphorylated (p)-EGFR, AKT1, p-AKT1, AKT2, p-AKT2, ERK1, ERK2, p-ERK1/2, STAT3,
and p-STAT3 was assessed by immunohistochemical analysis of tissue microarrays for 275 ESCC patients who had
undergone complete three-field lymphadenectomy. Spearman rank correlation tests were used to determine the
relationships among protein expression, and Cox regression analyses were performed to determine the prognostic
factors on overall survival (OS).
Results: p-EGFR expression was correlated statistically with all of the other phosphorylated markers. Gender, N
stage, and p-AKT1 expression were found to be independent prognostic factors for OS. Increased expression of
p-AKT1 was associated with decreased patient survival. EGFR and p-EGFR expression was not significantly
associated with patient survival.
Conclusion: Activation of AKT1 was associated with poor prognosis in ESCC.
Keywords: Esophageal carcinoma, Esophageal squamous cell carcinoma, Epidermal growth factor receptor,
p-AKT1, Prognostic factor, Prognosis, Immunohistochemistry
Background
Esophageal cancer (EC) is a common malignancy world-
wide, with Asia being one of the high-prevalence areas
[1]. Although the incidence rates for esophageal adeno-
carcinoma have been increasing in several Western
countries, esophageal squamous cell carcinoma (ESCC)
is the most common histological type in Eastern coun-
tries, such as China, where it accounts for more than
90 % of EC cases [2]. Despite improvements in surgical
techniques, perioperative management, and surgery
combined with chemotherapy and/or radiotherapy, the
prognosis for ESCC remains poor, particularly in ad-
vanced stages [3]. Therefore, the development of new
therapy modalities, particularly targeted therapies based
on knowledge of the biology and genetics of the disease,
may offer the potential for improving treatment re-
sponse and quality of life for ESCC patients.
In the past decade, great interest has been directed
toward the use of agents targeting cell surface receptors
that are responsible for the development and progression
of various cancers. Epidermal growth factor receptor
(EGFR) is one of the most commonly altered receptors in
human malignancies. This receptor is mainly involved in
regulating cellular processes including cell apoptosis, pro-
liferation, angiogenesis, migration, and adhesion through
activation of PI3K-Akt, STAT3, and Ras-Raf-MAPK
signaling pathways [4]. In a variety of human cancers,
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increased expression of EGFR has been identified and
shown to be associated with advanced disease, develop-
ment of metastases, and poor clinical prognosis in a sub-
set of these cancers [5]. However, study results on the
prognostic effect of EGFR in ESCC remain conflicting
[6–10]. To investigate the role of EGFR-related pathway
activities in ESCC progression, we used tissue micro-
array (TMA) technology and immunohistochemical
(IHC) analysis to evaluate the activities of EGFR and its
downstream effectors AKT, ERK, and STAT3 in ESCC;
we also analyzed the relationships of these markers and
their association with prognosis in ESCC patients.
Materials and methods
Study population
We have performed a series of studies to explore the
clinical and biological prognostic factors in thoracic
ESCC in patients who underwent complete three-field
lymphadenectomy (3FLND) [11, 12]. We reviewed the
pathology reports of all patients with EC who under-
went 3FLND at our hospital between 2001 and 2009,
and 354 patients were selected on the basis of the fol-
lowing clinical criteria: having pathologically confirmed
thoracic ESCC; having only one primary tumor; not
receiving preoperative chemotherapy and/or radiother-
apy; having undergone 3FLND with ≥15 total lymph
nodes removed; and having tumor-free resection of
margins by microscopic examination of the surgical
specimen. Of these patients, 22 were excluded from ana-
lysis because of perioperative deaths (2 patients) and lost
to follow-up (20 patients). Among the remaining 332
patients, paraffin specimens were not available for 57;
thus, 275 patients were selected for this study.
The preoperative workup, surgical procedure, and
criteria for adjuvant treatment and follow-up were de-
scribed elsewhere [11, 12]. The clinicopathologic charac-
teristics of the study population are summarized in
Table 1. This study was approved by the Institutional
Review Board, which waived the requirement for written
informed consent of individual patients, given the retro-
spective nature of this study.
TMA construction and IHC analysis
TMAs were constructed in collaboration with the Depart-
ment of Pathology at our hospital according to established
methods [13]. For each patient, the tumor was identified
on the original hematoxylin and eosin-stained (H&E)
slides, and the corresponding formalin-fixed, paraffin-
embedded tissue blocks were obtained. With use of a
UATM-272A Tissue Microarrayer (Unitma, Seoul, Korea),
three 1-mm tissue cores which were punched from vari-
ous areas of the predominant tumor population and one
1-mm normal tissue cone which were punched from the
normal areas around tumor for each patient and deposited
into a 12 ×10 TMA block (120 cores). IHC staining was
performed on 4-μm paraffin-embedded sections from
TMA blocks by the standard Envision method using a
panel of antibodies: EGFR (113, dilution 1:50; Dako),
AKT1 (C73H10, dilution 3 μg/ml; Cell Signaling), AKT2
(302501, dilution 25 μg/ml; R&D), ERK1 (Y72, dilution
Table 1 Clinicopathologic characteristics of 275 patients
included in our study












<5 cm 123 (44.7)
≥5 cm 152 (55.3)
Tumor differentiation
Well differentiated 26 (9.5)
Moderately differentiated 184 (66.9)
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1:100; Abcam), ERK2 (E460, dilution 1:250; Abcam), STA
T3 (E121-21, dilution 1:50; Abcam), phosphorylated-EG
FR (p-EGFR) (Tyr1068) (EP774Y, dilution 1:250; Abcam),
phosphorylated-AKT1 (p-AKT1) (Ser473) (EP2109Y, dilu-
tion 1:100; Abcam), phosphorylated-AKT2 (p-AKT2) (Ser
474) (D3H2, dilution 1:100; Cell Signaling), phospho
rylated-ERK1/2 (p-ERK1/2) (MAPK-YT, dilution 1:100;
Abcam), and phosphorylated- STAT3 (p-STAT3) (EP2147
Y, dilution 1:250; Abcam) (Fig. 1).
IHC scoring
A modified semiquantitative method H-score was used
to evaluate IHC staining [14, 15]. For each tissue core, a
score was generated by multiplying the percentages of
positive cells (0–100 %) and the intensity of staining. For
EGFR and p-EGFR, the staining intensity was classified
as follows: 0, no staining; 1+, partial membrane staining;
2+, weak, complete membrane staining; 3+, moderate,
complete membrane staining; and 4+, strong, complete
Fig. 1 Representative findings on immunohistochemical staining for the tested biomarkers (original magnification × 200): EGFR, phosphorylated
(p)-EGFR, AKT1, p-AKT1, AKT2, p-AKT2, ERK1, ERK2, p-ERK1/2, STAT3, and p-STAT3
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membrane staining. For the other markers, the staining
intensity for IHC reaction was classified as follows: 0,
negative; 1+, weak; 2+, moderate; and 3+, strong. Thus,
the overall H-score ranged from 0 to 400 (EGFR or p-
EGFR) or 0 to 300 (the other markers). All immunos-
tains were evaluated independently by three pathologists
and discordant cases were reevaluated; consensus was
reached with use of a multiheaded microscope.
Statistical analysis
Continuous variables were summarized by descriptive
statistics, such as means, standard deviations (SD), me-
dians, and ranges. Categorical variables were tabulated by
frequency and percentage. The survival functions were
computed from the date of surgery by using Kaplan-Meier
estimates, and the log-rank test was used to assess the
equality of survival functions. Spearman rank correlation
tests were used to assess the relationships among protein
expression. Since there’s at present no consensus which
cut-off points were best for the markers we tested, we
arbitrarily chose the median H-score values as the cut-
points for the categorical analyses: the marker was consid-
ered high expression with the H-score of ≥ the median
value, and low expression with the H-score of < the
median value. The univariate and multivariate Cox regres-
sion analyses were performed to test for the independent
influence of potential prognostic factors on overall sur-
vival (OS). Probability (P) values <0.05 were considered
statistically significant, and statistical tests were based on a
two-sided significance level. Statistical analyses were per-
formed with use of Statistical Package for the Social
Sciences software (SPSS, Chicago, IL).
Results
Correlation between EGFR expression and AKT, ERK and
STAT3 in ESCC
EGFR and p-EGFR staining were predominantly located
in the cell membrane. AKT1, AKT2, ERK1, ERK2, and
STAT3 immunoreactivity was mainly located in the
cytoplasm. p-AKT1, p-AKT2, p-ERK1/2, and p-STAT3
expression was detected in both the cytoplasm and
nucleus. Due to the inevitable loss of biopsy cores or
insufficient tumor cells present in the cores, about 2–5
cases were missed for each marker staining. The pa-
tients who missed any data of marker staining were
excluded, and left 270 patients for the final analysis. All
of the marker expression results are summarized in
Table 2.
Results from Spearman rank correlation analyses among
EGFR, p-EGFR, p-AKT1, pAKT2, p-ERK1/2, and p-STAT3
showed that EGFR expression was correlated with that of
p-EGFR (P = 0.001), p-AKT1 (P < 0.001) and p-AKT2 (P <
0.001) but not with that of p-ERK1/2 (P = 0.630) or p-
STAT3 (P = 0.835); p-EGFR expression was correlated
statistically with that of p-AKT1 (P < 0.001), p-AKT2 (P <
0.001), p-ERK1/2 (P = 0.027), and p-STAT3 (P < 0.001). p-
AKT1, p-AKT2, p-ERK1/2, and p-STAT3 expressions was
correlated with each other except for that between p-AKT2
and p-ERK1/2 (Table 3).
Clinical significance of phosphorylated-AKT1 in ESCC
At a median follow-up time of 34 months (range: 2–125
months), the median OS for the entire cohort was
39 months (95 % confidence interval [CI]: 20–58 months),
and survival rates were 52.5 % at 3 years and 45.2 % at
5 years (Fig. 2). The variables tested on univariate analysis
showed that the factors that were significantly associated
with OS included gender, N stage, adjuvant therapy, and
expression of p-AKT1 (Table 4). On multivariate analysis,
gender, N stage, and p-AKT1 expression were found to be
the independent prognostic factors for OS (Table 4).
When expression of p-AKT1 increased, patients’ survival
duration decreased (HR: 2.682, 95 % CI: 1.891–3.802).
Log-rank tests of overall survival comparing patients with
p-AKT1 high expression (H-scores ≥ 70) and those with
p-AKT1 low expression (H-scores < 70) show that the
group with p-AKT1 low expression had significantly
better OS than did the group with high expression among
all patients (P < 0.001, Fig. 3a), patients with stage I-II
diease (P < 0.001, Fig. 3b) and patients with stage III dis-
ease (P < 0.001, Fig. 3c).
Discussion
In this study, we tested the protein expression and activ-
ities of EGFR as well as several key nodes on its down-
stream pathways for ESCC patients and found that
expression of p-AKT1, p-AKT2, p-ERK1/2, and p-STAT3
was significantly related to the expression of p-EGFR. We
also found that activation of AKT1 independently influ-
enced patients’ survival, with higher expression of p-AKT1
being linked to poorer OS; neither EGFR nor p-EGFR
Table 2 Expression of proteins in quartiles of H-scores
Median Minimum Maximum 25 % 75 %
EGFR 80 0 400 0 160
p-EGFR 10 0 400 0 50
AKT1 30 0 240 5 80
p-AKT1 (Ser473) 70 0 250 40 100
AKT2 0 0 120 0 20
p-AKT2 (Ser474) 0 0 80 0 10
ERK1 40 0 210 0 60
ERK2 70 0 250 30 100
p-ERK1/2 50 0 170 30 80
STAT3 50 0 300 30 80
p-STAT3 30 0 300 10 60
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expression, however, had a prognostic effect in ESCC
patients in this cohort.
Currently, the role of EGFR in tumor development in
ESCC is not clear, although elevated expression of
EGFR has been reported in 50–90 % of patients with
ESCC [16–20]. Several studies have shown that EGFR
overexpression was associated with poor OS and poor
disease-free survival in ESCC patients [6–8]; other
studies, however, did not find a prognostic effect for
EGFR overexpression in ESCC [9, 10]. The inconsistent
conclusions drawn from the various studies might be
due to differences in patient selection, treatments, and
the methods used for detecting and scoring EGFR
expression.
In the present study, the prognostic value of EGFR
was not found. Several researchers [9, 21] have reported
that EGFR expression has predictive value for the thera-
peutic effect of chemotherapy and radiotherapy in ESCC;
specifically, patients with elevated EGFR expression had
better treatment outcomes after chemoradiotherapy. To
rule out the influence of adjuvant chemotherapy and/or
radiotherapy in the prognosis, we performed Cox regres-
sion analyses for the 106 patients who did not receive
adjuvant therapy in our group and still found no associ-
ation between EGFR expression and OS (data not
shown). Our future work will explore whether alter-
ations of EGFR, including gene mutation and amplifica-
tion, have prognostic values in ESCC.
EGFR is a tyrosine kinase receptor, and the phosphor-
ylated tyrosine residue serves as a docking site to exert
its biological roles. After being phosphorylated, EGFR
is activated and then in turn activates multiple down-
stream intracellular signaling pathways, mainly PI3K-
Akt, STAT3, and Ras-Raf-MAPK pathways. Our finding
that p-EGFR was highly correlated to the phosphoryl-
ation of AKT1, AKT2, ERK1/2, and STAT3 indicated
that p-EGFR possibly contributed to the activation of
these downstream pathways in ESCC, suggesting that
the EGFR pathways might be active in some patients
with ESCC. However, we also observed that p-AKT1
could predict the prognosis of ESCC, while EGFR and
p-EGFR could not be, suggesting that the activation of
AKT1 resulted from other factors in some patients.
Besides EGFR stimulation, several other ways of activat-
ing AKT1 have been reported, including other growth
factor receptors such as VEGF and PDGF, mutations of
PI3K or RAS, inactivation of tumor suppressor gene
PTEN, and AKT1E17K somatic mutations [22–26]. The
exact mechanisms of this phenomenon in ESCC are
unclear and need further investigation.
AKT, a serine/threonine protein kinase, is the cen-
tral mediator of the canonical PI3K pathway, which
can mediate various cellular functions including cell
Table 3 Correlations of the protein expression: Spearman rank correlation tests
EGFR p-EGFR p-AKT1 p-AKT2 p-ERK1/2 p-STAT3
EGFR Correlation coefficient 1.000 0.196 0.269 0.226 −0.030 0.013
P value . 0.001 <0.001 <0.001 0.630 0.835
p-EGFR Correlation coefficient 0.196 1.000 0.337 0.331 0.135 0.390
P value 0.001 . <0.001 <0.001 0.027 <0.001
p-AKT1 Correlation coefficient 0.269 0.337 1.000 0.355 0.127 0.219
P value <0.001 <0.001 . <0.001 0.038 <0.001
p-AKT2 Correlation coefficient 0.226 0.331 0.355 1.000 0.018 0.180
P value <0.001 <0.001 <0.001 . 0.772 0.003
p-ERK1/2 Correlation coefficient −0.030 0.135 0.127 0.018 1.000 0.204
P value 0.630 0.027 0.038 0.772 . 0.001
p-STAT3 Correlation coefficient 0.013 0.390 0.219 0.180 0.204 1.000
P value 0.835 <0.001 <0.001 0.003 0.001 .
Fig. 2 Kaplan-Meier curve of overall survival for all patients
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Table 4 Univariate and multivariate for overall survival: Cox proportional hazards regression model
Prognostic factors OS
P value P value HR (95 % CI)
(univariate) (multivariate) (for multivariate)
Sex (male, female) 0.011 0.012 1.346 (1.071-1.803)
Age (≤60, >60 year) 0.373
Tumor location (upper, middle, lower) 0.277
Tumor length (<5 cm, ≥5 cm) 0.890
Tumor differentiation (well, moderately, poorly) 0.148
T stage (T1, T2, T3, T4) 0.128





Adjuvant therapy (none, chemotherapy, radiotherapy, chemoradiotherapy, unknown) 0.027
EGFR (≥80, <80) 0.735
p-EGFR (≥10, <10) 0.392
AKT1 (≥30, <30) 0.362
p-AKT1 (≥70, <70) <0.001 <0.001 2.682 (1.891–3.802)
AKT2 (>0, =0) 0.179
p-AKT2 (>0, =0) 0.379
ERK1 (≥40, <40) 0.683
ERK2 (≥70, <70) 0.558
p-ERK1/2 (≥50, <50) 0.209
STAT3 (≥50, <50) 0.233
p-STAT3 (≥30, <30) 0.621
HR, hazard ratio; CI, confidence interval; OS = overall survival
Fig. 3 Log-rank tests of overall survival comparing patients with p-AKT1 H-scores of ≥70 and those with p-AKT1 H-scores of <70 for (a) all
patients (n = 270; P < 0.001); b stage I-II patients (n = 128; P < 0.001); and c stage III patients (n = 142; P < 0.001)
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metabolism, growth, proliferation, survival, apoptosis,
and angiogenesis [27]. A number of studies have dem-
onstrated the overactivation of AKT in many human
solid tumors and hematological malignancies [28].
AKT has three isoforms: AKT1, AKT2, and AKT3. Al-
though these AKT family members share a similar domain
structure, they have distinct substrates and different
physiological behaviors [29]. These AKT isoforms seem to
mediate different functions in cancer pathophysiology; for
example, AKT1 appears to promote mammary tumor
induction, whereas AKT2 promotes metastasis in previous
reports [29, 30]. This may explain the difference in the
prognostic effects between p-AKT1 and p-AKT2 in ESCC
patients in our study.
The prognostic values of p-AKT1 have been studied
for several malignancies. Interestingly, many studies have
shown that activation of AKT1 was associated with poor
prognosis [31–33], whereas other studies have shown
AKT1 activation to be a favorable prognostic indicator
[34–36]. To the best of our knowledge, few studies have
examined the association between AKT1 activation and
clinical outcome in ESCC. Yoshioka et al. [37] used IHC
analysis to examine p-AKT expression in 235 ESCC
patients who underwent surgery with or without pre-
operative chemotherapy and found that p-AKT expres-
sion was associated with poor prognosis in those who
had received chemotherapy but did not correlate with
survival in those who had not received chemotherapy.
However, that study did not specify the isoform of
AKT1. Nowadays, the PI3K/AKT pathway has been rec-
ognized as an important pathway in the development of
cancers [38]. Our study suggested the potential of AKT1
as a target for anticancer therapeutics in ESCC.
Conclusion
Our study suggests p-AKT1 is associated with poor prog-
nosis in patients with ESCC, and supports further studies
to investigate the potential mechanisms.
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